Skip to main content
Brain Pathology logoLink to Brain Pathology
. 2024 Sep 1;35(1):e13302. doi: 10.1111/bpa.13302

The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors

Olivera Casar‐Borota 1,2,✉, Pia Burman 3, M Beatriz Lopes 4
PMCID: PMC11669403  PMID: 39218431

Abstract

The vast majority of pituitary neuroendocrine tumors (PitNETs) are benign and slow growing with a low relapse rate over many years after surgical resection. However, about 40% are locally invasive and may not be surgically cured, and about one percentage demonstrate an aggressive clinical behavior. Exceptionally, these aggressive tumors may metastasize outside the sellar region to the central nervous system and/or systemically. The 2017 (4th Edition) WHO Classification of Pituitary Tumors abandoned the terminology “atypical adenoma” for tumors previously considered to have potential for a more aggressive behavior since its prognostic value was not established. The 2022 (5th Edition) WHO Classification of the Pituitary Tumors emphasizes the concept that morphological features distinguish indolent tumors from locally aggressive ones, however, the proposed histological subtypes are not consistent with the real life clinical characteristics of patients with aggressive tumors/carcinomas. So far, no single clinical, radiological or histological parameter can determine the risk of growth or malignant progression. Novel promising molecular prognostic markers, such as mutations in ATRX, TP53, SF3B1, and epigenetic DNA modifications, will need to be verified in larger tumor cohorts. In this review, we provide a critical analysis of the WHO guidelines for prognostic stratification and diagnosis of aggressive and metastatic PitNETs. In addition, we discuss the new WHO recommendations for changing ICD‐O and ICD‐11 codes for PitNET tumor behavior from a neoplasm either “benign” or “unspecified, borderline, or uncertain behavior” to “malignant” neoplasm regardless of the clinical presentation, histopathological subtype, and tumor location. We encourage multidisciplinary initiatives for integrated clinical, histological and molecular classification, which would enable early recognition of these challenging tumors and initiation of more appropriate and aggressive treatments, ultimately improving the outcome.

Keywords: metastatic pituitary tumor, PitNET, pituitary adenoma, pituitary carcinoma, pituitary neuroendocrine tumor

1. INTRODUCTION

Anterior pituitary gland neoplasms have been designated as tumors more than a century ago [1, 2]. The terms tumor and adenoma have been interchangeably used through the time. Early on, both secretory and mass effects of the adenohypophysial tumors were recognized as it was “realized that the tumor need not necessarily be bulky but, quite to the contrary, striking clinical effects might be produced by minute, symptomatically predictable adenomas” [3]. Although typically benign and treatable by surgery and pharmacological therapy, rare adenohypophysial tumors may behave aggressively and even metastasize. The term pituitary carcinoma has for decades been used to designate anterior pituitary neoplasms spreading within or outside the central nervous system [4]. Previously, the term “atypical adenoma” was applied to adenohypophysial tumors showing increased proliferation defined by increased mitotic account and proliferative index Ki‐67 as well as an extensive expression of p53 by immunohistochemistry. [4] Since then a synonymous use of the histological term “atypical adenoma” and the clinical term “aggressive adenoma” has frequently raised confusion. Clinically aggressive PitNETs have been defined as “large, radiologically confirmed invasive lesions with an unusually rapid growth, or clinically relevant growth despite optimal standard therapies” [5].

In the recent WHO classifications [4, 6], the term “atypical adenoma” has been abandoned, but precise designation of the clinically aggressive tumors is lacking. Assessment of pituitary tumor staging/invasion, an important feature of clinically aggressive PitNETs, is not considered. Instead, certain histological subtypes have been associated with potentially more aggressive behavior. Of these, sparsely‐granulated somatotroph tumors may be more invasive and less responsive to standard somatostatin receptor 2 (SSTR2) targeting medical therapy, mostly related to the lower expression of SSTR2 on tumor cells [7, 8, 9, 10]. Silent corticotroph tumors develop at younger age and demonstrate invasive growth and recurrence more frequently than silent gonadotroph tumors according to some studies [11, 12, 13, 14], but not others [15, 16]. Experience with other “high‐risk PitNETs” such as immature PIT1 lineage PitNETs [17], Crooke cell [18], and acidophilic stem cell tumors [19], is limited. Null‐cell tumors represent a controversial category [20] and it is questionable whether aggressive tumors reported in the literature as null‐cell adenomas [21] fulfill the strict criteria for being classified as PitNETs. The prognostic value of the proposed “high‐risk” histological subtypes according to the WHO classifications has not been verified in larger studies of PitNETs with the exception of the silent corticotroph tumors [11, 12, 13, 14, 15, 16]. Recently, the addition of “high‐risk” PitNETs has been assigned as a risk factor in a clinicopathological classification proposed by the Pituitary Society [22].

From the aspects of pituitary tumor and neuroendocrine tumor biology, assessment of proliferative markers such as mitotic count and Ki‐67 index, seems more relevant; however, no cut off levels were provided by the 2022 WHO classification [6]. Expression of the tumor suppressor TP53 by immunohistochemistry has been removed from the current classification as a criterium suggestive of aggressiveness of PitNETs [6]. Although not a histopathological parameter, tumor invasiveness figures as a prognostic factor in the WHO classification [6], and is an essential prognostic factor in the five‐tired classification proposed by Trouillas et al [23]. However, uncertainty regarding the definition of invasiveness in PitNETs and the fact that MRI information on tumor invasiveness is usually not provided to the pathologist limit the use of this parameter in routine assessment. Moreover, the Trouillas classification [23] well identifies tumors with high risk of recurrence after surgery, but was not developed to identify the uncommon aggressive and metastatic PitNETs.

Despite a broad integration of molecular pathology in the classification of tumors of the central nervous system, genetic factors have not yet been included in the classification of PitNETs, even when their prognostic value has been confirmed.

A terminology change from “pituitary adenoma” to “pituitary neuroendocrine tumor/PitNET” was proposed in 2017 by The International Pituitary Pathology Club [24] and supported by the International Agency for Research on Cancer (IARC) and an WHO expert group [25]. The intention was to introduce a terminology that reflects the biological nature of the anterior pituitary neoplasms, and also covers the spectrum of phenotypes from harmless intrasellar lesions to the aggressive, therapy resistant and, in exceptional cases, metastatic neoplasms. This broad spectrum of behaviors has been unfortunately not properly addressed by the international coding agencies [25, 26] which resulted in controversial coding of all PitNETs as malignant neoplasms, and also discrepant coding through different WHO classifications [6, 27, 28].

In this review, we will (1) provide an update on the WHO classification of metastatic PitNETs, (2) discuss pathological, molecular and clinical aspects of aggressive, and metastatic PitNETs, and (3) give a critical view on a controversial coding system applied to PitNETs in the current WHO classification.

2. CURRENT DEFINITION OF METASTATIC PITUITARY NEUROENDOCRINE TUMORS ACCORDING TO THE WHO 2022 CLASSIFICATION

In the current WHO classification, the term pituitary neuroendocrine tumor (PitNET) was proposed and the designation metastatic PitNET introduced [6], although the term pituitary carcinoma is still considered acceptable. A main argument for terminology “metastatic PitNET” instead of “pituitary carcinoma” is to avoid confusion with neuroendocrine carcinoma, a term used to designate a poorly differentiated epithelial neuroendocrine neoplasm in other organs. Metastatic PitNET is defined as “A tumor of adenohypophysial neuroendocrine cells that manifests metastatic disease to lymph nodes and distant sites, or that has discontinuous spread through the central nervous system”. Furtherly, “It also remains to be determined whether primary poorly differentiated pituitary NENs exist that would qualify for classification as neuroendocrine carcinoma (NEC) based on the WHO/IARC framework” [6].

There are no histological characteristics that indicate metastatic potential in PitNETs. Although increased mitotic activity and high Ki‐67 proliferative index at initial or later surgeries suggest aggressive behavior, these histological features do not predict metastatic dissemination. Moreover, tumors with benign histology and low cell proliferation at the initial surgery may develop an aggressive, and metastatic phenotype (Figure 1). In the European Society of Endocrinology (ESE) surveys on aggressive and metastatic pituitary tumors, proliferative indices were highly variable. Ki‐67 ≤ 3% at the first surgery was observed in 15% of 150 patients [29]. Similarities between aggressive and metastatic tumors regarding proportion of corticotroph tumors, increased Ki‐67 and mitotic index as well as a relatively frequent p53 overexpression motivated proposal for the designation “pituitary tumor with malignant potential without metastasis” for aggressive PitNETs [30].

FIGURE 1.

FIGURE 1

Initial first surgery specimens from three different pituitary carcinomas showing a highly variable cell proliferation: A GH‐PRL producing carcinoma with no mitoses in haematoxylin‐eosin staining (A) and a low Ki‐67 index <1% (B), a corticotroph carcinoma with scattered mitoses (C) and moderately elevated Ki‐67 index 5%–8% (D), and a corticotroph carcinoma with high mitotic rate (E) and Ki‐67 > 40% (F). Hematoxylin–eosin microphotographs are taken with 400× magnification and Ki‐67 immunostaining captured with 200× magnification. Mitoses are highlighted with arrows.

3. GENETIC AND EPIGENETIC FACTORS PREDICTIVE OF AGGRESSIVENESS AND METASTATIC POTENTIAL IN PitNETs

Molecular characterization of PitNETs has been instrumental for understanding and diagnostic application of the terminal lineage differentiation of these tumors [31, 32, 33, 34]. However genomic, transcriptomic, and epigenetic analyses of PitNETs have been of limited value in predicting tumor behavior, mostly due to rarity of aggressive and metastatic PitNETs and lack of studies on the larger cohorts.

Recent studies have demonstrated that mutations in the ATRX gene are associated with tumor aggressive clinical behavior mainly in the corticotroph subtype [35, 36]. This assay has been applied in the routine work‐up at some pathology centers. Since the mutated ATRX protein is absent or modified and thus not recognized at immunohistochemistry, a negative immunostaining can be used as a simple screening method. In the lactotroph tumors, SF3B1 mutations were recently shown to be associated with aggressive behavior and metastatic dissemination [37, 38, 39]. An increasing number of publications have demonstrated TP53 gene mutations in aggressive tumors, especially in the corticotroph [36, 40, 41, 42, 43, 44, 45, 46, 47, 48], but also in the lactotroph tumors [39, 49]. However, studies on TP53 mutational status in non‐aggressive PitNETs are rare [39, 47]. To our knowledge, TP53 mutations have not been reported in benign tumor types, except a single corticotroph tumor recently reported [39]. Since correlations between TP53 gene alterations and immunohistochemical expression of the p53 protein remain unclear, the prognostic value of p53 immunostaining is debated. Other genes reported altered in sporadic cases of aggressive and metastatic PitNETs are CDKN2A/2B [36, 50, 51], PTEN [36, 52, 53], Rb [36, 54, 55], DAXX [43], reviewed and listed in tab. S1 in Burman 2023 [29]. USP8 is frequently mutated in benign corticotroph tumors [31, 56, 57, 58], but rarely in their aggressive or metastatic counterparts [45, 47, 59].

Differences in genome‐wide DNA methylation and proteomic profiling have recently been detected in non‐functioning tumors with and without postsurgical progression [60, 61]. However, methylation data on tumors fulfilling the strict criteria for aggressiveness have not yet been published.

Data on copy number variation (CNV) pattern and aggressiveness are sparse. There is an association between disrupted CNV and size and invasiveness, but not recurrence rate in corticotroph tumors [45]. Recently, genome wide loss of heterozygosity was shown to correlate with aggressiveness and therapy‐resistance in a cohort of 26 aggressive and metastatic tumors, mostly of corticotroph type [39].

Interestingly, a single cell RNA sequencing study revealed the presence of different cell subpopulations in PitNETs according to their degree of differentiation—well‐differentiated and poorly‐differentiated—within their specific cell‐lineage tumor subtype (PIT1, TPIT and SF1 lineages). The differentiation status was related to long‐term recurrence in an independent cohort of 800 cases, including higher recurrence rates in both poorly differentiated tumors in PIT1 and TPIT lineages, whereas higher recurrence rates correlated surprisingly with the markers of well‐differentiated tumors in SF1 lineage tumors [62].

Although studies like these are promising, the use of molecular markers with potential prognostic or therapeutic application has not yet bridged into diagnostic practice in pituitary tumor pathology.

Pituitary tumors associated with germline mutations causing multiple endocrine neoplasia (MEN) 1 and familial isolated pituitary adenoma syndrome (FIPA) present at a younger age, and are more often less responsive to treatment with somatostatin analogues [63]. However, they do not seem to be associated with a higher risk for developing an aggressive and metastatic course. There are single case reports of aggressive and metastatic tumors in patients with MEN1 [64, 65, 66], one case with an AIP [67], and succinate dehydrogenase genes [68] mutations, respectively. So far, five cases of aggressive PitNETs have been reported in patients with Lynch syndrome, an autosomal dominantly inherited cancer predisposing syndrome caused by defective mismatch repair mechanisms (MLH1, MSH2, MSH6, PMS2) [69, 70, 71, 72]. Of these, one corticotroph tumor with concomitant ATRX mutation developed metastatic disease [36, 69]. Since tumors with mismatch repair mutations in general are susceptible to treatment with immune check point inhibitors, a family history/ other manifestations of Lynch syndrome, should be asked for in the work up of aggressive PitNETs/PCs.

There are no genetic factors with confirmed association especially to metastatic disease in PitNETs. ATRX, TP53, and SF3B1mutations have all been identified in both carcinomas and aggressive non‐metastatic tumors [36, 38, 47]; however, follow‐up periods have been relatively short limiting the possibility to assess the impact on the metastatic potential. Thus, genetic and epigenetic studies on larger cohorts of aggressive and metastatic PitNETs are warranted to characterize genetic landscape of these rare tumors and allow for the integration of molecular features into the classification of PitNETs.

We have summarized histological and molecular genetic factors with negative prognostic impact in PitNETs in Table 1.

TABLE 1.

Overview of the PitNET features reported to have negative prognostic impact.

Histopathological subtypes

  • Sparsely granulated somatotroph PitNET/adenoma [6, 7, 8, 9, 10]
  • Silent corticotroph PitNET/adenoma [6, 11, 12, 13, 14, 15]
  • Immature PIT1‐lineage PitNET/adenoma [6, 17]
  • Crooke cell PitNET/adenoma [6, 18]
  • Acidophilic stem cell PitNET/adenoma [6, 19]

Tumor invasion and cell proliferation

  • Local invasion [21, 23]
  • Increased mitotic count [6, 21]
  • Increased Ki‐67 index [6, 21, 27, 73, 74]

Molecular genetic factors

Somatic mutations
Germline mutations
  • Mismatch repair genes MSH2, MSH6, MLH1/Lynch syndrome [29, 69, 70, 71, 72]
Epigenetic alterations
  • Disrupted CNV pattern in corticotroph tumors [39, 45]

4. CLINICAL EXPERIENCES REGARDING AGGRESSIVE AND METASTATIC PitNETs

Aggressive and metastatic PitNETs usually present as invasive “macroadenomas”, less frequently as giant tumors (largest diameter ≥4 cm), and display a highly variable clinical course. The most common subtypes are corticotroph and lactotroph tumors (Figure 2). Functioning corticotroph tumors (Cushing's disease) represent 40%–50% of the aggressive tumors, and 60% of the patients are men. This differs from the situation among “ordinary” non‐aggressive PitNETs where only 5%–10% have Cushing's disease and the typical patient is a woman [75]. Among non‐functioning aggressive and metastatic PitNETs, silent corticotroph tumors (SCT) and tumors of the PIT1 cell lineage are overrepresented [29]. The gonadotroph subtype was estimated to comprise up to a third of cases, however the cell lineage had not always been determined making the precise assessment difficult [73]. In comparison, in surgical series of “ordinary” non‐functioning PitNETs more than 70% [76, 77] were gonadotroph tumors, indicating that gonadotroph tumors have low propensity for malignant transformation.

FIGURE 2.

FIGURE 2

Tumor size at the first presentation in 50 patients with pituitary carcinomas. Of the 12 non‐functioning PCs hormone immunohistochemistry was positive for prolactin (n = 1), growth hormone (3), adrenocorticotroph hormone (4), transcription factor PIT1 (2), and not investigated (2). Two of the silent somatotroph, and 3 of the silent corticotroph PCs subsequently became functioning.

Silent aggressive and metastatic PitNETs, especially SCTs, may occasionally evolve into hormone‐secreting tumors. Such a change has been reported in 5% of non‐aggressive SCTs [12, 78]; in one study, the shift was associated with an increased tumor expression of prohormone convertase 1/3 [79]. In the ESE survey on aggressive and metastatic PitNETs, 5 of 13 SCTs and 2 of 8 silent somatotroph tumors subsequently became functioning [29, 73]. The shifts were mostly observed either prior to or in parallel with progression of the pituitary tumor, and, in a few cases, in parallel with detection of metastases [73].

Aggressive and metastatic PitNETs may initially behave as most “benign” pituitary tumors, e.g., respond to standard therapy, surgery, medical drugs (dopamine agonists and somatostatin analogues) and/ or radiotherapy, and later change their clinical course. In patients with lactotroph tumors, this is exemplified by loss of an initial good response to cabergoline, resulting in an enlarging tumor and increasing prolactin levels despite increasing doses of the drug. In the ESE survey encompassing 171 aggressive tumors (50 carcinomas), about half of them were initially considered as benign based on their clinical behavior, and demonstrated an aggressive course after a median 5.5 years from diagnosis [73]. The tumors in the “initially clinically benign” group displayed lower proliferative indices and were less often p53 immunopositive at the first surgery compared with tumors with an aggressive course from outset [73]. The time to metastases was also longer in the “initially benign” group.

Pituitary carcinomas metastasize to the craniospinal region, and/or systemically, most often to bone and the liver (but also to the lung and lymph nodes). The liver and bone seem more often targeted in corticotroph and lactotroph carcinomas, whilst clinically silent tumors more often disseminate to the CNS [73, 80]. The time from diagnosis to detection of metastases is highly variable with average 5–9 years, range 0.5–34 [73, 81, 82, 83]. Metastatic tumors with Ki‐67 > 10% at the first pituitary surgery disseminate earlier than the tumors with lower Ki‐67 indices [73, 74].

Most aggressive tumors are identified only after multiple recurrences after surgery or upon progression after radiotherapy. Metastatic tumors behave similarly to the aggressive ones but are only identified after dissemination. The following clinical characteristics should raise a suspicion of an aggressive tumor ‐ a man with an invasive corticotroph macroadenoma, macro/giant lactotroph tumors initially not responding to, or losing sensitivity to dopamine agonists, somatotroph tumors demonstrating increasing GH levels /tumor progression while on somatostatin analogues, and patients with non‐functioning invasive macroadenomas switching to clinically functioning, especially those becoming ACTH secreting [73, 84].

With the exception of SCTs, histological PitNET types classified as “high‐risk” tumors in the WHO classification [6] are very rare tumors, and do not seem to be prevalent among aggressive and malignant pituitary tumors. The clinical relevance of a “high risk tumor” defined by histology can therefore be questioned. Of interest, ATRX, SF3B1, and TP53 mutations have been demonstrated already at the first surgery, even in tumors which developed an aggressive phenotype several years later [36, 38]. This underlines importance of a further search for molecular markers for an early identification of patients at risk of developing aggressive and malignant PitNETs.

5. MALIGNANCY GRADING AND ICD CODING SYSTEM FOR PitNETs

The spectrum of PitNETs clinical presentation from indolent tumors to locally invasive tumors, and to more aggressive tumors with repeated recurrences, therapy resistance, and ultimately metastatic disease fits the overall model of NEN/NET from other organs and systems. As commented in ENDO5, “a rational and coherent classification system has been proposed for NENs for a unified approach to these lesions, while recognizing that important organ‐specific differences exist” [6]. A major difference between PitNETs and other NETs is the lack of grading and staging systems. Although NETs in most locations are graded in a three‐tier system (G1–G3) with defined guidelines, this grading system is not applied to pituitary tumors. Most NETs in other organs are G1 or G2 and similar to PitNETs almost indolent, high‐grade G3 NETs occur in a variable incidence according to tumor location [25]. The gray zone between aggressive and metastatic PitNETs is broad. Whether aggressive non‐metastatic and metastatic pituitary tumors differ genetically is unclear. The histological features are similar and so is the clinical course before metastatic spread [30, 84]. This may be an argument for introduction of the term “malignant PitNETs” encompassing both aggressive non‐metastatic and metastatic pituitary tumors.

A Ki‐67 index >10% is suggestive of aggressive and metastatic PitNETs as it was found in 41% of the aggressive tumors and in 61% of the carcinomas reported to the second ESE survey [73], whereas in <3% of “benign” PitNETs [85]. Similarly to NETs in other organs, absence of increased proliferation markers in the histological specimens does not exclude the possibility of an aggressive phenotype. For instance, Ki‐67 at the first pituitary surgery was ≤3% in 15% of the tumor specimens in a cohort of 150 aggressive and metastatic pituitary tumors [29]. Identification of molecular genetic alterations in combination with histological markers will likely improve the prognostic value, as shown in other types of tumors, and in perspective justify use of the term pituitary neuroendocrine carcinoma (PitNEC), as previously suggested [48, 86].

In line with this reasoning, ICD‐O code 8272/3 for pituitary neuroendocrine tumor with malignancy grade 3 can be justified for highly proliferative PitNETs with genetic alterations associated with malignant phenotype. However, the International Classification of Diseases for Oncology (ICD‐O) coding through the 5th Edition of WHO classifications [6, 27, 28] defines all PitNETs as malignant (8272/3) regardless if a pituitary in situ tumor or metastatic PitNET. On the other hand, a discrepancy is seeing with the International Classification of Diseases (ICD‐11) coding reported between the 5th Endocrine WHO classification [6], which classifies all PitNETs as “2D12.Y: Other specified malignant neoplasms of other endocrine glands or related structures”, and the ICD‐11 coding giving for the same tumors in the central nervous system (CNS) [27] and pediatric tumors [28] classifications (2F37.Y & XH94U0 Other specified benign neoplasm of endocrine glands & Pituitary adenoma, NOS; and 2F9A & XH94U0 Neoplasms of unknown behaviour of endocrine glands & Pituitary adenoma, NOS).

Current use of the ICD‐O code 8272/3 for all PitNETs regardless location, histological and molecular characteristics, invasiveness and other clinical features as already spelled out in the WHO current classifications [6, 27, 28] seems misleading. Similarly, ICD‐11 code 2D12.Y “Other specified malignant neoplasms of other endocrine glands or related structures” applied to all PitNETs according to the current WHO classification of endocrine tumors [6] is misleading as it incorrectly staple all PitNETs as malignant despite indolent behavior and benign histology in the vast majority of the tumors.

It appears that the WHO rationale is in reverse labeling the majority indolent tumors as tumors with potential for aggressive behavior and metastatic disease that corresponds to the minority and rare PitNETs. Given the spectrum of clinical behavior of the majority of PitNETs, it seems that ICD‐O code/1 (unspecified, borderline, or uncertain behavior) would be more appropriate for the majority of PitNETs and reserving ICD‐O code /3 for the highly proliferative PitNETs and metastatic PitNETs. Likewise, preferably, the code 2F9A & XH94U0 “Neoplasms of unknown behavior of endocrine glands” should be used, as applied in WHO CNS classification [27].

6. CLOSING REMARKS

Further refinement of the category of aggressive and metastatic pituitary neuroendocrine tumors can be obtained through increased knowledge on molecular alterations predisposing for aggressive and metastatic behavior. An integrated clinical, histological and molecular classification of PitNETs, in line with the classification of the tumors in the central nervous system, is essential for stratification of patients in regard to optimized follow‐up and therapeutic protocols. This goal will require multicenter efforts to establish large cohorts of these rare tumors and an interdisciplinary approach. Present discrepancies and confusions in the ICD coding system for pituitary tumors are contraproductive and should be timely coordinated between the different classification systems. As long as reliable markers of aggressiveness and malignancy are lacking, it is correct to designate pituitary neuroendocrine tumors as “neoplasms of uncertain behavior.”

AUTHOR CONTRIBUTIONS

OC‐B and MBL recommended the structure of the review. PB contributed with clinical comments and discussions. All the authors wrote and edited the manuscript and approved the final version of the manuscript.

Casar‐Borota O, Burman P, Lopes MB. The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors. Brain Pathology. 2025;35(1):e13302. 10.1111/bpa.13302

DATA AVAILABILITY STATEMENT

Data sharing is not aplicable as no original data were created or presented in the review.

REFERENCES

  • 1. Benda C. Beiträge zur normalen und pathologischen Histologie der menschlichen Hypophysis cerebri. Klin Wochenschr. 1900;37(52):1205–1210. [Google Scholar]
  • 2. Kraus EJ. Die Beziehungen der Zellen des Vorderlappens des menschlichen Hypophyse zeuinander unter normalen Verhältnissen und in Tumoren. Beitr z Path Anat u z Alg Path. 1914;58:159–210. [Google Scholar]
  • 3. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp. 1932;50:137–195. [Google Scholar]
  • 4. Lloyd RV, Osamura RY, Kloppel G, Rosai J. World Health Organization classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017. [Google Scholar]
  • 5. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1–G24. [DOI] [PubMed] [Google Scholar]
  • 6. WHO Classification of Tumours Editorial Board . Endocrine and neuroendocrine tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2022. [cited 2024 June 1]. (WHO classification of tumours series, 5th ed.; vol. 10). Available from: https://tumourclassification.iarc.who.int/chapters/53 [Google Scholar]
  • 7. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab. 2005;90:6290–6295. [DOI] [PubMed] [Google Scholar]
  • 8. Fougner SL, Casar‐Borota O, Heck A, Berg JP, Bollerslev J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf). 2012;76:96–102. [DOI] [PubMed] [Google Scholar]
  • 9. Bakhtiar Y, Hirano H, Arita K, Yunoue S, Fujio S, Tominaga A, et al. Relationship between cytokeratin staining patterns and clinico‐pathological features in somatotropinomae. Eur J Endocrinol. 2010;163:531–539. [DOI] [PubMed] [Google Scholar]
  • 10. Swanson AA, Erickson D, Donegan DM, Jenkins SM, Van Gompel JJ, Atkinson JLD, et al. Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary. 2021;24:192–206. [DOI] [PubMed] [Google Scholar]
  • 11. Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson‐Chazot F, Lachuer J, et al. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol. 2010;163:35–43. [DOI] [PubMed] [Google Scholar]
  • 12. Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S, et al. A comprehensive long term retrospective analysis of silent corticotrophic adenomas vs hormone‐negative adenomas. Neurosurgery. 2013;73:8–17. [DOI] [PubMed] [Google Scholar]
  • 13. Cooper O. Silent corticotroph adenomas. Pituitary. 2015;18:225–231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Goyal‐Honavar A, Sarkar S, Asha HS, Kapoor N, Balakrishnan R, Vanjare H, et al. A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary‐specific transcription factors. Acta Neurochir. 2021;163(11):3143–3154. [DOI] [PubMed] [Google Scholar]
  • 15. Fountas A, Lavrentaki A, Subramanian A, Toulis KA, Nirantharakumar K, Karavitaki N. Recurrence of silent corticotroph adenomas after primary treatment: a systematic review and meta‐analysis. J Clin Endocrinol Metab. 2019;104:1039–1048. [DOI] [PubMed] [Google Scholar]
  • 16. Chatrath A, Kosyakovsky J, Patel P, Ahn J, Elsarrag M, Young LC, et al. Impact of histopathological classification of non‐functioning adenomas on long term outcomes: comparison of the 2004 and 2017 WHO classifications. Pituitary. 2022;25(6):988–996. [DOI] [PubMed] [Google Scholar]
  • 17. Mete O, Gomez‐Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit‐1 lineage adenomas. Mod Pathol. 2016;29:131–142. [DOI] [PubMed] [Google Scholar]
  • 18. George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, et al. Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol. 2003;27:1330–1336. [DOI] [PubMed] [Google Scholar]
  • 19. Horvath E, Kovacs K, Singer W, Smith HS, Killinger DW, Erzin C, et al. Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer. 1981;47:761–771. [DOI] [PubMed] [Google Scholar]
  • 20. Manojlovic‐Gacic E, Bollerslev J, Casar‐Borota O. Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint. Neuropathol Appl Neurobiol. 2020;46(2):89–110. [DOI] [PubMed] [Google Scholar]
  • 21. Almeida JP, Stephens CC, Eschbacher JM, Felicella MM, Yuen KCJ, Whitel WL, et al. Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. Pituitary. 2019;22:514–519. [DOI] [PubMed] [Google Scholar]
  • 22. Ho KKY, Fleseriu M, Wass J, Katznelson L, Raverot G, Little AS, et al. A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis. Lancet Diabetes Endocrinol. 2024;12(3):209–214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Trouillas J, Roy P, Sturm N, Dantony E, Cortet‐Rudelli C, Viennet G, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case‐control study of 410 patients with 8 years post‐operative follow‐up. Acta Neuropathol. 2013;126:123–135. [DOI] [PubMed] [Google Scholar]
  • 24. Asa SL, Casar‐Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017;24:C5–C8. [DOI] [PubMed] [Google Scholar]
  • 25. Rindi G, Klimstra D, Abedi‐Ardekani B, Asa S, Bosman F, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31:1770–1786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. International classification of diseases eleventh revision (ICD‐11). Geneva: World Health Organization; 2022. License: CC BY‐ND 3.0 IGO. [Google Scholar]
  • 27. WHO Classification of Tumours Editorial Board . Central nervous system tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2021. [cited 2024 June 1]. (WHO classification of tumours series, 5th ed.; vol. 6). Available from: https://tumourclassification.iarc.who.int/chapters/45 [Google Scholar]
  • 28. WHO Classification of Tumours Editorial Board . Paediatric tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2022. [cited 2024 June 1]. (WHO classification of tumours series, 5th ed.; vol. 7). Available from: https://tumourclassification.iarc.who.int/chapters/44 [Google Scholar]
  • 29. Burman P, Casar‐Borota O, Perez‐Rivas LG, Dekkers OM. Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment. J Clin Endocrinol Metab. 2023;108(7):1585–1601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Trouillas J, Burman P, McCormack A, Petersenn S, Popovic V, Dekkers O, et al. Aggressive pituitary tumours and carcinomas: two sides of the same coin? Eur J Endocrinol. 2018;178:C7–C9. [DOI] [PubMed] [Google Scholar]
  • 31. Neou M, Villa C, Armignacco R, Jouinot A, Raffin‐Sanson ML, Septier A, et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell. 2020;37(1):123–134.e5. [DOI] [PubMed] [Google Scholar]
  • 32. Taniguchi‐Ponciano K, Andonegui‐Elguera S, Peña‐Martínez E, Silva‐Román G, Vela‐Patiño S, Gomez‐Apo E, et al. Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors. Sci Rep. 2020;10(1):19373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Mosella MS, Sabedot TS, Silva TC, Malta TM, Dezem FS, Asmaro KP, et al. DNA methylation‐based signatures classify sporadic pituitary tumors according to clinicopathological features. Neuro Oncol. 2021;23(8):1292–1303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Tebani A, Jotanovic J, Hekmati N, Sivertsson Å, Gudjonsson O, Engström BE, et al. Annotation of pituitary neuroendocrine tumors with genome‐wide expression analysis. Acta Neuropathol Commun. 2021;9(1):181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Casar‐Borota O, Botling J, Granberg D, Stigare J, Wikström J, Boldt HB, et al. Serotonin, ATRX, and DAXX expression in pituitary adenomas: markers in the differential diagnosis of neuroendocrine tumors of the sellar region. Am J Surg Pathol. 2017;41:1238–1246. [DOI] [PubMed] [Google Scholar]
  • 36. Casar‐Borota O, Boldt HB, Engström BE, Andersen MS, Baussart B, Bengtsson D, et al. Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations. J Clin Endocrinol Metab. 2021;106(4):1183–1194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Li C, Xie W, Rosenblum JS, Zhou J, Guo J, Miao Y, et al. Somatic SF3B1 hotspot mutation in prolactinomas. Nat Commun. 2020;11:2506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Simon J, Perez‐Rivas LG, Zhao Y, Chasseloup F, Lasolle H, Cortet C, et al. Prevalence and clinical correlations of SF3B1 variants in lactotroph tumors. Eur J Endocrinol. 2023;189(3):372–378. [DOI] [PubMed] [Google Scholar]
  • 39. Lin AL, Rudneva VA, Richards AL, Zhang Y, Woo HJ, Cohen M, et al. Genome‐wide loss of heterozygosity predicts aggressive, treatment‐refractory behavior in pituitary neuroendocrine tumors. Acta Neuropathol. 2024;147:85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV. P53 gene mutations in pituitary carcinomas. Endocr Pathol. 2007;18(4):217–222. [DOI] [PubMed] [Google Scholar]
  • 41. Kawashima S‐T, Usui T, Sano T, Iogawa H, Hagiwara H, Tamanaha T, et al. P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease. Clin Endocrinol (Oxf). 2009;70(4):656–657. [DOI] [PubMed] [Google Scholar]
  • 42. Pinto EM, Siqueira SACC, Cukier P, Fragoso MCBV, Lin CJ, de Mendonca BB. Possible role of a radiation‐induced p53 mutation in a Nelson's syndrome patient with a fatal outcome. Pituitary. 2011;14(4):400–404. [DOI] [PubMed] [Google Scholar]
  • 43. Sbiera S, Perez‐Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in USP8 wild‐type Cushing's disease. Neuro Oncol. 2019;21(10):1273–1283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Uzilov AV, Taik P, Cheesman KC, et al. Data from “integrative genomic analysis of a corticotroph adenoma cohort enriched for aggressive and atypical tumors reveals an association of copy number variant landscape with USP8 and TP53 driver status.” Dryad Deposited August 1, 2020. 10.5061/dryad.pnvx0k6jt [DOI]
  • 45. Uzilov AV, Taik P, Cheesman KC, Javanmard P, Ying K, Roehnelt A, et al. USP8 and TP53 drivers are associated with CNV in a corticotroph adenoma cohort enriched for aggressive tumors. J Clin Endocrinol Metab. 2021;106(3):826–842. [DOI] [PubMed] [Google Scholar]
  • 46. Guaraldi F, Morandi L, Zoli M, Mazzatenta D, Righi A, Evangelisti S, et al. Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients. Clin Endocrinol (Oxf). 2022;97(6):763–772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Perez‐Rivas LG, Simon J, Albani A, Tang S, Roeber S, Assié G, et al. TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome. Acta Neuropathol Commun. 2022;10(1):139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Saeger W, Mawrin C, Meinhardt M, Wefers AK, Jacobsen F. Two pituitary neuroendocrine tumors (PitNETs) with very high proliferation and TP53 mutation ‐ high‐grade PitNET or PitNEC? Endocr Pathol. 2022;33(2):257–262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, et al. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin‐producing pituitary carcinoma: case report. Neurosurgery. 2011;68(6):1761–1767. [DOI] [PubMed] [Google Scholar]
  • 50. Kara M, Tokat F, Pamir MN, Danyeli AE. Frequency and role of CDKN2A deletion in high‐risk pituitary neuroendocrine tumors. Endocr Pathol. 2020;31(2):166–173. [DOI] [PubMed] [Google Scholar]
  • 51. Medina EJ, Zohdy YM, Porto E, Revuelta Barbero JM, Bray D, Maldonado J, et al. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas. Front Endocrinol (Lausanne). 2023;14:1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Guo F, Wang G, Wang F, Xu D, Liu X. Identification of novel genes involved in the pathogenesis of an ACTH‐secreting pituitary carcinoma: a case report and literature review. Front Oncol. 2018;8:510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Sumislawski P, Rotermund R, Klose S, Lautenbach A, Wefers AK, Soltwedel C, et al. ACTH‐secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations. Case report and review of the literature. Endocrine. 2022;76(1):228–236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res. 1995;55(8):1613–1616. [PubMed] [Google Scholar]
  • 55. Ikeda H, Beauchamp RL, Yoshimoto T, Yandell DW. Detection of heterozygous mutation in the retinoblastoma gene in a human pituitary adenoma using PCR‐SSCP analysis and direct sequencing. Endocr Pathol. 1995;6(3):189–196. [DOI] [PubMed] [Google Scholar]
  • 56. Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nat Genet. 2015;47(1):31–38. [DOI] [PubMed] [Google Scholar]
  • 57. Ma Z‐Y, Song Z‐J, Chen J‐H, Wang J‐F, Li S‐Q, Zhou L‐F, et al. Recurrent gain‐of‐function USP8 mutations in Cushing's disease. Cell Res. 2015;25(3):306–317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Pérez‐Rivas LG, Theodoropoulou M, Ferraù F, Nusser C, Kawaguchi K, Stratakis CA, et al. The gene of the ubiquitin‐specific protease 8 is frequently mutated in adenomas causing Cushing's disease. J Clin Endocrinol Metab. 2015;100(7):E997–E1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Andonegui‐Elguera S, Silva‐Román G, Peña‐Martínez E, Taniguchi‐Ponciano K, Vela‐Patiño S, Remba‐Shapiro I, et al. The genomic landscape of corticotroph tumors: from silent adenomas to ACTH‐secreting carcinomas. Int J Mol Sci. 2022;23(9):4861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Hallén T, Johannsson G, Dahlén R, Glad CAM, Örndal C, Engvall A, et al. Genome‐wide DNA methylation differences in nonfunctioning pituitary adenomas with and without postsurgical progression. J Clin Endocrinol Metab. 2022;107(8):2318–2328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Hallén T, Johannsson G, Thorsell A, Olsson DS, Örndal C, Engvall A, et al. Proteomic profiles associated with postsurgical progression in non‐functioning pituitary adenomas. J Clin Endocrinol Metab. 2024;109(6):1485–1493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Zhang Q, Yao B, Long X, Chen Z, He M, Wu Y, et al. Single‐cell sequencing identifies differentiation‐related markers for molecular classification and recurrence prediction of PitNET. Cell Rep Med. 2023;4(2):100934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Dénes J, Korbonits M. The clinical aspects of pituitary tumour genetics. Endocrine. 2021;71:663–674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Gordon MV, VarmaD MLCA, Bittar RG, Burgess JR, Topliss DJ. Metastatic prolactinoma presenting as a cervical spinal cord tumour in multiple endocrine neoplasia type one (MEN‐1). Clin Endocrinol (Oxf). 2007;66(1):150–152. [DOI] [PubMed] [Google Scholar]
  • 65. Scheithauer BW, Kovacs K, Nose V, Lombardero M, Osamura YR, Lloyd RV, et al. Multiple endocrine neoplasia type 1‐associated thyrotropin‐producing pituitary carcinoma: report of a probable de novo example. Hum Pathol. 2009;40(2):270–278. [DOI] [PubMed] [Google Scholar]
  • 66. Bengtsson D, Schrøder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, et al. Long‐term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab. 2015;100:1689–1698. [DOI] [PubMed] [Google Scholar]
  • 67. Dutta P, Reddy KS, Rai A, Madugundu AK, Solanki HS, Bhansali A, et al. Surgery, octreotide, temozolomide, bevacizumab, radiotherapy, and pegvisomant treatment of an AIP mutation–positive child. J Clin Endocrinol Metab. 2019;104(8):3539–3544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Tufton N, Roncaroli F, Hadjidemetriou I, Dang MN, Denés J, Guasti L, et al. Pituitary carcinoma in a patient with an SDHB mutation. Endocr Pathol. 2017;28:320–325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Bengtsson D, Joost P, Aravidis C, Askmalm Stenmark M, Backman AS, Melin B, et al. Corticotroph pituitary carcinoma in a patient with lynch syndrome (LS) and pituitary tumors in a nationwide LS cohort. J Clin Endocrinol Metab. 2017;102(11):3928–3932. [DOI] [PubMed] [Google Scholar]
  • 70. Uraki S, Ariyasu H, Doi A, Furuta H, Nishi M, Sugano K, et al. Atypical pituitary adenoma with MEN1 somatic mutation associated with abnormalities of DNA mismatch repair genes; MLH1 germline mutation and MSH6 somatic mutation. Endocr J. 2017;64(9):895–906. [DOI] [PubMed] [Google Scholar]
  • 71. Loughrey PB, Baker G, Herron B, Cooke S, Iacovazzo D, Lindsay JR, et al. Invasive ACTH‐producing pituitary gland neoplasm secondary to MSH2 mutation. Cancer Genet. 2021;256‐257:36–39. [DOI] [PubMed] [Google Scholar]
  • 72. Teuber J, Reinhardt A, Reuss D, Hähnel S, Unterberg A, Beynon C, et al. Aggressive pituitary adenoma in the context of lynch syndrome: a case report and literature review on this rare coincidence. Br J Neurosurg. 2021;25:1–6. [DOI] [PubMed] [Google Scholar]
  • 73. Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, et al. Aggressive pituitary tumors and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol. 2022;187(4):593–605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Raymond P, Raverot G, Ilie MD. Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review. Endocr Relat Cancer. 2023;30(5):e220338. [DOI] [PubMed] [Google Scholar]
  • 75. Molitch ME. Diagnosis and treatment of pituitary adenomas. A review. JAMA. 2017;317(5):516–524. [DOI] [PubMed] [Google Scholar]
  • 76. Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol. 2015;26:349–355. [DOI] [PubMed] [Google Scholar]
  • 77. Sjöstedt E, Bollerslev J, Mulder J, Lindskog C, Pontén F, Casar‐Borota O. A specific antibody to detect transcription factor T‐pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours. Acta Neuropathol. 2017;134:675–677. [DOI] [PubMed] [Google Scholar]
  • 78. Langlois F, Tim DST, Yedinak CG, Cetas I, McCartney S, Cetas J, et al. Predictors of silent corticotroph adenoma recurrence: a large retrospective single center study and systematic literature review. Pituitary. 2018;21:32–40. [DOI] [PubMed] [Google Scholar]
  • 79. Righi A, Faustini‐Fustini M, Morandi L, Monti V, Asioli S, Mazzatenta D, et al. The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3. Endocrine. 2017;56:286–297. [DOI] [PubMed] [Google Scholar]
  • 80. Lenders N, McCormack A. Malignant transformation in non‐functioning pituitary adenomas. Pituitary. 2018;21:217–229. [DOI] [PubMed] [Google Scholar]
  • 81. Dudziak K, Honegger J, Bornemann A, Horger M, Müssig K. Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course – case report and review of the literature. J Clin Endocrinol Metab. 2011;96:2665–2669. [DOI] [PubMed] [Google Scholar]
  • 82. Yoo F, Kuan EC, Heaney AP, Bergsneider M, Wang MB. Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary. 2018;21:290–301. [DOI] [PubMed] [Google Scholar]
  • 83. Santos‐Pinheiro F, Penas‐Prado M, Kamiya‐Matsuoka C, Waguespack SG, Mahajan A, Brown PD, et al. Treatment and long‐term outcomes in pituitary carcinoma: a cohort study. Eur J Endocrinol. 2019;181:397–407. [DOI] [PubMed] [Google Scholar]
  • 84. McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumors and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178:265–276. [DOI] [PubMed] [Google Scholar]
  • 85. Trouillas J, Burman P, Losa M, McCormack A, Petersenn S, Popovic V, et al. Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b? – that is the question. Eur J Endocrinol. 2023;188:C1–C5. [DOI] [PubMed] [Google Scholar]
  • 86. Asa SL, Ezzat S. Pituitary carcinoma: reclassification and implications in the NET schema. Endocrine. Oncology. 2022;2(1):R14–R23. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing is not aplicable as no original data were created or presented in the review.


Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES